Blueprint Medicines Corp (BPMC) Expected to Post Earnings of -$1.83 Per Share

Brokerages expect that Blueprint Medicines Corp (NASDAQ:BPMC) will report ($1.83) earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for Blueprint Medicines’ earnings, with the lowest EPS estimate coming in at ($2.02) and the highest estimate coming in at ($1.64). Blueprint Medicines reported earnings per share of ($0.62) during the same quarter last year, which would indicate a negative year-over-year growth rate of 195.2%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that Blueprint Medicines will report full-year earnings of ($7.76) per share for the current year, with EPS estimates ranging from ($8.55) to ($6.73). For the next fiscal year, analysts forecast that the company will report earnings of ($7.71) per share, with EPS estimates ranging from ($8.13) to ($7.26). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.98) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.83) by ($0.15). Blueprint Medicines had a negative net margin of 603.88% and a negative return on equity of 59.26%. The firm had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.38 million. During the same period in the prior year, the company posted ($1.29) earnings per share. The company’s revenue for the quarter was down 23.2% on a year-over-year basis.

A number of equities research analysts have commented on BPMC shares. Zacks Investment Research raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a research report on Tuesday, April 30th. BidaskClub downgraded shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 16th. Cowen reissued a “buy” rating on shares of Blueprint Medicines in a research report on Tuesday, February 26th. Wedbush reissued an “outperform” rating on shares of Blueprint Medicines in a research report on Tuesday, February 26th. Finally, Morgan Stanley started coverage on shares of Blueprint Medicines in a research report on Wednesday, April 3rd. They issued an “overweight” rating and a $112.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Blueprint Medicines currently has a consensus rating of “Buy” and a consensus price target of $102.17.

Shares of NASDAQ:BPMC traded down $0.04 during trading hours on Friday, reaching $81.05. The stock had a trading volume of 4,470 shares, compared to its average volume of 398,508. Blueprint Medicines has a 1 year low of $44.58 and a 1 year high of $89.00. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27. The company has a market cap of $3.96 billion, a PE ratio of -15.02 and a beta of 1.53.

In other news, insider Marion Dorsch sold 2,300 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $84.66, for a total value of $194,718.00. Following the completion of the transaction, the insider now owns 2,300 shares in the company, valued at approximately $194,718. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ariel Hurley sold 415 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $85.55, for a total transaction of $35,503.25. Following the completion of the transaction, the insider now owns 415 shares of the company’s stock, valued at approximately $35,503.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 44,359 shares of company stock valued at $3,798,843. Company insiders own 3.15% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. LPL Financial LLC acquired a new stake in Blueprint Medicines during the 3rd quarter worth $411,000. Vanguard Group Inc. boosted its stake in Blueprint Medicines by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 3,735,390 shares of the biotechnology company’s stock worth $291,584,000 after purchasing an additional 111,972 shares during the period. Rhumbline Advisers boosted its stake in Blueprint Medicines by 46.1% during the 4th quarter. Rhumbline Advisers now owns 55,349 shares of the biotechnology company’s stock worth $2,984,000 after purchasing an additional 17,475 shares during the period. SG Americas Securities LLC boosted its stake in Blueprint Medicines by 485.3% during the 4th quarter. SG Americas Securities LLC now owns 9,962 shares of the biotechnology company’s stock worth $537,000 after purchasing an additional 8,260 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its stake in Blueprint Medicines by 2.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 24,671 shares of the biotechnology company’s stock worth $1,330,000 after purchasing an additional 595 shares during the period. Institutional investors and hedge funds own 93.93% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Recommended Story: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.